The controversy over Marathon’s pricing of the steroid deflazacort is fueling calls to revisit the US Orphan Drug Act. For Big Pharma companies, the threat should not be ignored. It is time for the industry’s biggest players to take back development of products like deflazacort to protect pricing for more innovative therapies.
The story about the approval of Marathon Pharmaceuticals LLC’s Duchenne Muscular Dystrophy drug Emflaza (deflazacort) should be a heartwarming tale of another success of the Orphan Drug Act.
When the law was enacted more than three decades ago, the focus was on products exactly like this one: a...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
